Sectors & Industries HealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2026)
Top general drug manufacturer stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best general drug manufacturer stocks to buy now. Learn More.

Industry: Drug Manufacturers - Gene...

Zen Rating Price Value Growth Financials Momentum Sentiment Forecast Dividends Due Diligence

General Drug Manufacturers is Zen Rated A and is the 10th ranked industry out of 145 stock market industries

Ticker	Company	Exchange	Industry	Market Cap	Price	1d %	EBITDA	P/E	D/E	Country
GSK	GSK PLC	NYSE	Drug Manufacturers - General	$119.61B	$59.52	-2.19%	$15.49B	15.40x	2.76	United Kingdom
BMY	BRISTOL MYERS SQUIBB CO	NYSE	Drug Manufacturers - General	$123.53B	$60.66	0.60%	$13.34B	17.48x	3.87	United States
GRFS	GRIFOLS SA	NASDAQ	Drug Manufacturers - General	$6.46B	$9.40	-0.42%	$1.71B	36.72x	2.18	United States
ABBV	ABBVIE INC	NYSE	Drug Manufacturers - General	$397.50B	$224.81	0.21%	$17.36B	94.86x	-41.95	United States
LLY	ELI LILLY & CO	NYSE	Drug Manufacturers - General	$952.34B	$1,009.52	-1.34%	$27.73B	43.89x	3.24	United States
SNY	SANOFI	NASDAQ	Drug Manufacturers - General	$114.04B	$46.76	-1.31%	$17.97B	12.27x	0.77	France
AZN	ASTRAZENECA PLC	NYSE	Drug Manufacturers - General	$316.51B	$204.20	-2.12%	$19.83B	30.94x	1.34	United Kingdom
GILD	GILEAD SCIENCES INC	NASDAQ	Drug Manufacturers - General	$187.84B	$151.40	0.19%	$13.67B	23.26x	1.72	United States
MRK	MERCK & CO INC	NYSE	Drug Manufacturers - General	$303.45B	$122.26	0.33%	$27.65B	16.15x	1.50	United States
AMRN	AMARIN CORP PLC	NASDAQ	Drug Manufacturers - General	$324.16M	$15.59	-0.83%	-$80.28M	-3.71x	0.44	Ireland
OGN	ORGANON & CO	NYSE	Drug Manufacturers - General	$2.11B	$8.10	7.71%	$1.56B	4.20x	13.96	United States
AMGN	AMGEN INC	NASDAQ	Drug Manufacturers - General	$202.02B	$374.75	-0.20%	$16.90B	26.15x	9.46	United States
JNJ	JOHNSON & JOHNSON	NYSE	Drug Manufacturers - General	$584.38B	$242.49	-1.79%	$41.06B	21.79x	1.44	United States
BIIB	BIOGEN INC	NASDAQ	Drug Manufacturers - General	$28.18B	$192.03	-0.03%	$2.34B	21.75x	0.61	United States
PFE	PFIZER INC	NYSE	Drug Manufacturers - General	$151.52B	$26.65	-0.78%	$15.84B	15.49x	1.25	United States
NVS	NOVARTIS AG	NYSE	Drug Manufacturers - General	$310.40B	$162.67	-0.76%	$28.74B	22.56x	1.40	Switzerland
SCLX	SCILEX HOLDING CO	NASDAQ	Drug Manufacturers - General	$61.59M	$8.12	1.37%	-$319.06M	-0.25x	-2.54	United States
MIRA	MIRA PHARMACEUTICALS INC	NASDAQ	Drug Manufacturers - General	$49.83M	$1.19	-1.24%	-$5.60M	-0.45x	0.01	United States
MDCX	MEDICUS PHARMA LTD	NASDAQ	Drug Manufacturers - General	$25.99M	$1.18	7.27%	-$29.72M	-0.55x	-11.85	United States
NSRX	NASUS PHARMA LTD	NYSEMKT	Drug Manufacturers - General	$53.16M	$5.90	18.00%	N/A	N/A	-1.15	Israel

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Feb 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:

1. Gsk (NYSE:GSK)

Gsk (NYSE:GSK) is the #1 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Gsk (NYSE:GSK) is: Value: B, Growth: B, Momentum: B, Sentiment: C, Safety: B, Financials: B, and AI: C.

Gsk (NYSE:GSK) has a Due Diligence Score of 36, which is -4 points lower than the general drug manufacturer industry average of 40. Although this number is below the industry average, our proven quant model rates GSK as a "A".

GSK passed 13 out of 38 due diligence checks and has average fundamentals. Gsk has seen its stock return 61.04% over the past year, overperforming other general drug manufacturer stocks by 37 percentage points.

2. Bristol Myers Squibb Co (NYSE:BMY)

Bristol Myers Squibb Co (NYSE:BMY) is the #2 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Bristol Myers Squibb Co (NYSE:BMY) is: Value: A, Growth: C, Momentum: C, Sentiment: C, Safety: A, Financials: B, and AI: C.

Bristol Myers Squibb Co (NYSE:BMY) has a Due Diligence Score of 46, which is 6 points higher than the general drug manufacturer industry average of 40.

BMY passed 16 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock return 8.73% over the past year, underperforming other general drug manufacturer stocks by -16 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $61.42, an upside of 1.25% from Bristol Myers Squibb Co's current stock price of $60.66.

Bristol Myers Squibb Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Bristol Myers Squibb Co, 41.67% have issued a Strong Buy rating, 8.33% have issued a Buy, 41.67% have issued a hold, while 0% have issued a Sell rating, and 8.33% have issued a Strong Sell.

3. Grifols Sa (NASDAQ:GRFS)

Grifols Sa (NASDAQ:GRFS) is the #3 top general drug manufacturer stock out of 20 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Grifols Sa (NASDAQ:GRFS) is: Value: A, Growth: B, Momentum: C, Sentiment: C, Safety: C, Financials: C, and AI: C.

Grifols Sa (NASDAQ:GRFS) has a Due Diligence Score of 35, which is -5 points lower than the general drug manufacturer industry average of 40. Although this number is below the industry average, our proven quant model rates GRFS as a "A".

GRFS passed 13 out of 38 due diligence checks and has average fundamentals. Grifols Sa has seen its stock return 24.83% over the past year.

Grifols Sa has an average 1 year price target of $10.00, an upside of 6.38% from Grifols Sa's current stock price of $9.40.

Grifols Sa stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Grifols Sa, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 14 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Pfizer (NYSE:PFE)

Pfizer (NYSE:PFE) has an annual dividend yield of 4.84%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.63%. Pfizer's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Pfizer's dividend has shown consistent growth over the last 10 years.

Pfizer's dividend payout ratio of 99.4% indicates that its high dividend yield might not be sustainable for the long-term.

2. Sanofi (NASDAQ:SNY)

Sanofi (NASDAQ:SNY) has an annual dividend yield of 4.73%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.63%. Sanofi's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Sanofi's dividend has shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 58.1% indicates that its high dividend yield is sustainable for the long-term.

3. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) has an annual dividend yield of 4.2%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.63%. Organon & Co's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Organon & Co's dividend has not shown consistent growth over the last 10 years.

Organon & Co's dividend payout ratio of 31.1% indicates that its high dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks down?

General drug manufacturer stocks were down -0.81% in the last day, and down -1.34% over the last week.

We couldn't find a catalyst for why general drug manufacturer stocks are down.

What are the most undervalued general drug manufacturer stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued general drug manufacturer stocks right now are:

1. Organon & Co (NYSE:OGN)

Organon & Co (NYSE:OGN) is the most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Organon & Co has a valuation score of 71, which is 32 points higher than the general drug manufacturer industry average of 39. It passed 5 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -48.37% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -73 percentage points.

2. Grifols Sa (NASDAQ:GRFS)

Grifols Sa (NASDAQ:GRFS) is the second most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Grifols Sa has a valuation score of 43, which is 4 points higher than the general drug manufacturer industry average of 39. It passed 3 out of 7 valuation due diligence checks.

Grifols Sa's stock has gained 24.83% in the past year. It has performed in line with other stocks in the general drug manufacturer industry.

3. Biogen (NASDAQ:BIIB)

Biogen (NASDAQ:BIIB) is the third most undervalued general drug manufacturer stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Biogen has a valuation score of 86, which is 47 points higher than the general drug manufacturer industry average of 39. It passed 6 out of 7 valuation due diligence checks.

Biogen's stock has gained 40.09% in the past year. It has overperformed other stocks in the general drug manufacturer industry by 16 percentage points.

Are general drug manufacturer stocks a good buy now?

40% of general drug manufacturer stocks rated by analysts are a strong buy right now. On average, analysts expect general drug manufacturer stocks to rise by 7.01% over the next year.

15.79% of general drug manufacturer stocks have a Zen Rating of A (Strong Buy), 36.84% of general drug manufacturer stocks are rated B (Buy), 36.84% are rated C (Hold), 5.26% are rated D (Sell), and 5.26% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 34.78x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.